Recurrence-associated chromosomal anomalies in meningiomas: Single-institution study and a systematic review with meta-analysis

Neurologia i Neurochirurgia Polska

Volumn 50, Issue 6, 2016, Pages 439-448

  Och, Waldemar ^a   Szmuda, Tomasz ^b   Sikorska, Beata ^c   Springer, Janusz ^b   Jaskólski, Dariusz ^c   Zakrzewska, Magdalena ^c   Liberski, Paweł P ^c  

^a Regional Specialistic Pediatric Hospital   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Individual patient data; Loss of heterozygosity; Meningioma; Meta analysis; Systematic review

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CHROMOSOME 14; CHROMOSOME 22; CHROMOSOME ABERRATION; CHROMOSOME ARM; FEMALE; FOLLOW UP; HETEROZYGOSITY LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; META ANALYSIS; RECURRENCE RISK; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; CHROMOSOME 1; DIAGNOSTIC IMAGING; GENETICS; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; ODDS RATIO; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 22; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; MAGNETIC RESONANCE IMAGING; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ODDS RATIO; PROGNOSIS; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84994181591     PISSN: 00283843     EISSN: 18974260     Source Type: Journal    
DOI: 10.1016/j.pjnns.2016.08.003     Document Type: Article

References (28)

1. [1] Choy, W., Kim, W., Nagasawa, D., Stramotas, S., Yew, A., Gopen, Q., et al. The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. Neurosurg Focus, 30, 2011, E6.
2. [2] Linsler, S., Kraemer, D., Driess, C., Oertel, J., Kammers, K., Rahnenführer, J., et al. Molecular biological determinations of meningioma progression and recurrence. PLoS ONE, 9, 2014, e94987.
3. [3] Norden, A.D., Drappatz, J., Wen, P.Y., Advances in meningioma therapy. Curr Neurol Neurosci Rep 9 (2009), 231–240.
4. [4] Lee, Y., Liu, J., Patel, S., Cloughesy, T., Lai, A., Farooqi, H., et al. Genomic landscape of meningiomas. Brain Pathol 20 (2010), 751–762.
5. [5] Commins, D.L., Atkinson, R.D., Burnett, M.E., Review of meningioma histopathology. Neurosurg Focus, 23, 2007, E3.
6. [6] Riemenschneider, M.J., Perry, A., Reifenberger, G., Histological classification and molecular genetics of meningiomas. Lancet Neurol 5 (2006), 1045–1054.
7. [7] Yew, A., Trang, A., Nagasawa, D.T., Spasic, M., Choy, W., Garcia, H.M., et al. Chromosomal alterations, prognostic factors, and targeted molecular therapies for malignant meningiomas. J Clin Neurosci 20 (2013), 17–22.
8. [8] Kim, Y-J., Ketter, R., Henn, W., Zang, K.D., Steudel, W.-I., Feiden, W., Histopathologic indicators of recurrence in meningiomas: correlation with clinical and genetic parameters. Virchows Arch 449 (2006), 529–538.
9. [9] Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K., Burger, P.C., Jouvet, A., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114 (2007), 97–109.
10. [10] Richterová, R., Jurečeková, J., Evinová, A., Kolarovszki, B., Benčo, M., De Riggo, J., et al. Most frequent molecular and immunohistochemical markers present in selected types of brain tumors. Gen Physiol Biophys 33 (2014), 259–279.
11. [11] Domingues, P.H., Sousa, P., Otero, Á., Gonçalves, J.M., Ruiz, L., de Oliveira, C., et al. Proposal for a new risk stratification classification for meningioma based on patient age, WHO tumor grade, size, localization, and karyotype. Neuro Oncol 16 (2014), 735–747.
12. [12] Hamilton, B.O., Sy, J.S., Megyesi, J.F., Ang, L.C., Her2neu amplification associates with Co-deletion 1p/14q in recurrent meningiomas. Can J Neurol Sci 40 (2013), 361–365.
13. [13] Ketter, R., Henn, W., Niedermayer, I., Steilen-Gimbel, H., König, J., Zang, K.D., et al. Predictive value of progression-associated chromosomal aberrations for the prognosis of meningiomas: a retrospective study of 198 cases. J Neurosurg 95 (2001), 601–607.
14. [14] Maíllo, A., Díaz, P., Sayagués, J.M., Blanco, A., Tabernero, M.D., Ciudad, J., et al. Gains of chromosome 22 by fluorescence in situ hybridization in the context of an hyperdiploid karyotype are associated with aggressive clinical features in meningioma patients. Cancer 92 (2001), 377–385.
15. [15] Pfisterer, W.K., Hendricks, W.P., Scheck, A.C., Nieman, R.A., Birkner, T.H., Krampla, W.W., et al. Fluorescent in situ hybridization and ex vivo 1H magnetic resonance spectroscopic examinations of meningioma tumor tissue: is it possible to identify a clinically-aggressive subset of benign meningiomas?. Neurosurgery 61 (2007), 1048–1059 discussion 1060–1.
16. [16] Pham, M.H., Zada, G., Mosich, G.M., Chen, T.C., Giannotta, S.L., Wang, K., et al. Molecular genetics of meningiomas: a systematic review of the current literature and potential basis for future treatment paradigms. Neurosurg Focus, 30, 2011, E7.
17. [17] Ragel, B.T., Jensen, R.L., Molecular genetics of meningiomas. Neurosurg Focus, 19, 2005, E9.
18. [18] Steudel, W.I., Feld, R., Henn, W., Zang, K.D., Correlation between cytogenetic and clinical findings in 215 human meningiomas. Acta Neurochir Suppl 65 (1996), 73–76.
19. [19] Tabernero, M.D., Maillo, A., Gil-Bellosta, C.J., Castrillo, A., Sousa, P., Merino, M., et al. Gene expression profiles of meningiomas are associated with tumor cytogenetics and patient outcome. Brain Pathol 19 (2009), 409–420.
20. [20] Sulman, E.P., Dumanski, J.P., White, P.S., Zhao, H., Maris, J.M., Mathiesen, T., et al. Identification of a consistent region of allelic loss on 1p32 in meningiomas: correlation with increased morbidity. Cancer Res 58 (1998), 3226–3230.
21. [21] Tabernero, M.D., Maíllo, A., Nieto, A.B., Diez-Tascón, C., Lara, M., Sousa, P., et al. Delineation of commonly deleted chromosomal regions in meningiomas by high-density single nucleotide polymorphism genotyping arrays. Genes Chromosomes Cancer 51 (2012), 606–617.
22. [22] Vogelbaum, M.A., Jost, S., Aghi, M.K., Heimberger, A.B., Sampson, J.H., Wen, P.Y., et al. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 70 (2012), 234–243 discussion 243–4.
23. [23] Kleihues, P., Sobin, L.H., World Health Organization classification of tumors. Cancer, 88, 2000, 2887.
24. [24] Ambekar, S., Sharma, M., Madhugiri, V.S., Nanda, A., Trends in intracranial meningioma surgery and outcome: a Nationwide Inpatient Sample database analysis from 2001 to 2010. J Neurooncol 114 (2013), 299–307.
25. [25] Pfisterer, W.K., Coons, S.W., Aboul-Enein, F., Hendricks, W.P., Scheck, A.C., Preul, M.C., Implicating chromosomal aberrations with meningioma growth and recurrence: results from FISH and MIB-I analysis of grades I and II meningioma tissue. J Neurooncol 87 (2008), 43–50.
26. [26] Tabernero, M.D., Espinosa, A.B., Maíllo, A., Sayagués, J.M., Alguero, M., del, C., et al. Characterization of chromosome 14 abnormalities by interphase in situ hybridization and comparative genomic hybridization in 124 meningiomas: correlation with clinical, histopathologic, and prognostic features. Am J Clin Pathol 123 (2005), 744–751.
27. [27] Higgins, J.P.T., Green, S., (eds.) The Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011), 2011, The Cochrane Collaboration Available from: www.cochrane-handbook.org.
28. [28] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6, 2009, e1000097.